Liu Yongjun resigned at the speed of light.

On December 9, according to media reports, Liu Yongjun had resigned from CSPC, just three months after the official announcement of joining.

On September 9 this year, CSPC issued an announcement on the Hong Kong Stock Exchange, announcing the appointment of Liu Yongjun as the group's executive president and global R&D president, responsible for the group's R&D, pipeline strategy and international business development.

It may be rare in the industry for a senior executive in this position to resign within three months. Combined with a series of personnel, capital and innovation strategy changes from CSPC to its innovative pharmaceutical subsidiary in the past three months, it can be seen that CSPC may be facing certain challenges in innovation, R&D, and internationalization.

This also highlights the fact that the transformation of most traditional pharmaceutical companies may end in failure. After all, innovation cannot be achieved simply by relying on R&D investment and recruiting corresponding positions, but requires a matching system and concept to ensure the combat effectiveness of the team.

Of course, this is just a reminder of the difficulty of transformation. It is obviously worth encouraging to actively embrace new trends. After all, only in this way can we avoid being eliminated by the times. However, constantly adapting to new challenges will be an ongoing topic.

https://mp.weixin.qq.com/